US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Genelux Corporation

2.98

+0.07762.68%

Volume:45.49K

Turnover:134.94K

Market Cap:111.05M

PE:-3.14

High:3.06

Open:2.88

Low:2.85

Close:2.90

Loading ...

Overview Company News Filings

Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year?

Benchmark Co. Remains a Buy on Genelux Corp. (GNLX)

Guggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX)

Genelux Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Genelux Q4 EPS ($0.95) Up From ($1.16) YoY

Genelux Corp: Expects Its Cash, Cash Equivalents & Short-Term Investments as of Dec 31, 2024 Will Provide Runway Into Q1 of 2026

THOMSON REUTERS

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

THOMSON REUTERS

Press Release: Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

BRIEF-Genelux Corp Enters Underwriting Agreement With Titan Partners Group- SEC Filing

Genelux Corp - Expects $10.5 Million Gross Proceeds From Offering - SEC Filing

THOMSON REUTERS

Genelux Corp - to Sell 3,000,000 Shares at $3.50 per Share - SEC Filing

THOMSON REUTERS

Genelux Corp - Enters Underwriting Agreement With Titan Partners Group- SEC Filing

THOMSON REUTERS

Genelux Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Genelux Announces FDA Guidance on Olvi-Vec Phase 3 Trial

MT Newswires Live

Genelux's Olvi-Vec Shows Anti-Tumor Effect in Phase 1b/2 Lung Cancer Study

MT Newswires Live

Genelux Prices $10.5 Million Stock Offering

MT Newswires Live

Genelux and Newsoara Announce Positive Preliminary Phase 1B/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer

THOMSON REUTERS

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GNLX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GNLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNLX\",,,,,undefined,":{"symbol":"GNLX","market":"US","secType":"STK","nameCN":"Genelux Corporation","latestPrice":2.9776,"timestamp":1745956117320,"preClose":2.9,"halted":0,"volume":45489,"delay":0,"floatShares":30736750,"shares":37294807,"eps":-0.949707,"marketStatus":"Trading","change":0.0776,"latestTime":"04-29 15:48:38 EDT","open":2.88,"high":3.06,"low":2.8501,"amount":134935.3762722,"amplitude":0.072379,"askPrice":3.02,"askSize":296,"bidPrice":2.97,"bidSize":248,"shortable":3,"etf":0,"ttmEps":-0.949707,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745956800000},"marketStatusCode":2,"adr":0,"listingDate":1674709200000,"exchange":"NASDAQ","adjPreClose":2.9,"preHourTrading":{"tag":"盘前","latestPrice":2.9,"preClose":2.9,"latestTime":"08:58 EDT","volume":31,"amount":89.70000350000001,"timestamp":1745931539229},"postHourTrading":{"tag":"盘后","latestPrice":3.04,"preClose":2.9,"latestTime":"17:53 EDT","volume":294,"amount":880.6,"timestamp":1745877194432},"volumeRatio":0.417946,"impliedVol":0.191,"impliedVolPercentile":0.1837},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNLX\",,,,,undefined,":{"symbol":"GNLX","floatShares":30736750,"roa":"-63.28%","roe":"-130.58%","lyrEps":-0.949707,"volumeRatio":0.417946,"shares":37294807,"dividePrice":0,"high":3.06,"amplitude":0.072379,"preClose":2.9,"low":2.8501,"week52Low":1.6,"pbRate":"4.23","psRate":"13881.13","week52High":5.885,"institutionHeld":0,"latestPrice":2.9776,"committee":-0.088235,"eps":-0.949707,"divideRate":0,"volume":45489,"delay":0,"ttmEps":-0.949707,"open":2.88,"prevYearClose":2.36,"prevWeekClose":2.88,"prevMonthClose":2.7,"prevQuarterClose":2.7,"fiveDayClose":2.94,"twentyDayClose":2.7,"sixtyDayClose":3.95},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GNLX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528170095","title":"Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2528170095","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528170095?lang=en_us&edition=fundamental","pubTime":"2025-04-18 21:40","pubTimestamp":1744983609,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. EUROFINS SCIENT  is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?Let's take a closer look at the stock's year-to-date performance to find out.EUROFINS SCIENT is a member of the Medical sector. This group includes 1002 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.Based on the latest available data, ERFSF has gained about 9.3% so far this year. At the same time, Medical stocks have lost an average of 5.6%. This means that EUROFINS SCIENT is outperforming the sector as a whole this year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eurofins-scient-erfsf-outperforming-other-134009853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GNLX","ERFSF"],"gpt_icon":0},{"id":"2525895120","title":"Benchmark Co. Remains a Buy on Genelux Corp. (GNLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525895120","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525895120?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:35","pubTimestamp":1744112115,"startTime":"0","endTime":"0","summary":"In a report released today, Bruce Jackson from Benchmark Co. maintained a Buy rating on Genelux Corp. (GNLX – Research Report), with a price target...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/benchmark-co-remains-a-buy-on-genelux-corp-gnlx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/benchmark-co-remains-a-buy-on-genelux-corp-gnlx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2524920376","title":"Guggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524920376","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524920376?lang=en_us&edition=fundamental","pubTime":"2025-04-04 19:36","pubTimestamp":1743766561,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Kelsey Goodwin from Guggenheim reiterated a Buy rating on Genelux Corp. (GNLX – Research Report), with a price targ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-genelux-corp-gnlx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-genelux-corp-gnlx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNLX"],"gpt_icon":0},{"id":"2523191798","title":"Genelux Price Target Maintained With a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2523191798","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523191798?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:02","pubTimestamp":1743418920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GNLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2025 07:02 ET (11:02 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX"],"gpt_icon":0},{"id":"2523468074","title":"Genelux Q4 EPS ($0.95) Up From ($1.16) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2523468074","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523468074?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:15","pubTimestamp":1743192907,"startTime":"0","endTime":"0","summary":"Genelux Q4 EPS ($0.95) Up From ($1.16) YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44545783/genelux-q4-eps-0-95-up-from-1-16-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX"],"gpt_icon":0},{"id":"2523680411","title":"Genelux Corp: Expects Its Cash, Cash Equivalents & Short-Term Investments as of Dec 31, 2024 Will Provide Runway Into Q1 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2523680411","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523680411?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:10","pubTimestamp":1743192601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA5KRZHG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2523680105","title":"Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523680105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523680105?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:10","pubTimestamp":1743192601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA5KRZHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2523434680","title":"Press Release: Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523434680","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523434680?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:10","pubTimestamp":1743192600,"startTime":"0","endTime":"0","summary":"Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update. -- Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer --. -- Matt Pulisic joined the company as its new Chief Financial Officer --. -- Closing of $10.5 Million Underwritten Offering of Common Stock --. -- $30.9 million in cash, cash equivalents and short-term investments --. WESTLAKE VILLAGE, Calif., March 28, 2025  -- Genelux Corporation , a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2024 financial results and business updates.\"Our progress in the fourth quarter of 2024 and into 2025 marks a pivotal period for patients, our company, and our investors,\" said Thomas Zindrick, President, CEO and Chairman of Genelux. \"We are pleased with the continued progress and promise of our clinical development program. The strengthening of our management team, with the addition of Matt, and of our balance sheet, with ou","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","OS","PFS","TM","BK4211","03160","BK4555","BK4585","BK4588","BK4604","GNLX","BK4139","BK4195","BK4099"],"gpt_icon":0},{"id":"2522836650","title":"BRIEF-Genelux Corp Enters Underwriting Agreement With Titan Partners Group- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522836650","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522836650?lang=en_us&edition=fundamental","pubTime":"2025-03-26 05:34","pubTimestamp":1742938448,"startTime":"0","endTime":"0","summary":"BRIEF-Genelux Corp Enters Underwriting Agreement With Titan Partners Group- SEC FilingMarch 25  - Genelux Corp GNLX.O:GENELUX CORP - ENTERS UNDERWRITING AGREEMENT WITH TITAN PARTNERS GROUP- SEC FILINGGENELUX CORP - TO SELL 3,000,000 SHARES AT $3.50 PER SHARE - SEC FILINGGENELUX CORP - EXPECTS $10.5 MILLION GROSS PROCEEDS FROM OFFERING - SEC FILINGSource text: [ID:n0001641172-25-000642]Further company coverage: GNLX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81B3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2522836555","title":"Genelux Corp - Expects $10.5 Million Gross Proceeds From Offering - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522836555","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522836555?lang=en_us&edition=fundamental","pubTime":"2025-03-26 05:29","pubTimestamp":1742938180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81B3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2522836553","title":"Genelux Corp - to Sell 3,000,000 Shares at $3.50 per Share - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522836553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522836553?lang=en_us&edition=fundamental","pubTime":"2025-03-26 05:29","pubTimestamp":1742938180,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81B3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2522383680","title":"Genelux Corp - Enters Underwriting Agreement With Titan Partners Group- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522383680","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522383680?lang=en_us&edition=fundamental","pubTime":"2025-03-26 05:29","pubTimestamp":1742938180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81B3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2522919004","title":"Genelux Price Target Maintained With a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522919004","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522919004?lang=en_us&edition=fundamental","pubTime":"2025-03-25 23:52","pubTimestamp":1742917920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GNLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 11:52 ET (15:52 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX"],"gpt_icon":0},{"id":"2522161008","title":"Genelux Announces FDA Guidance on Olvi-Vec Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2522161008","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522161008?lang=en_us&edition=fundamental","pubTime":"2025-03-25 22:21","pubTimestamp":1742912466,"startTime":"0","endTime":"0","summary":"Genelux  said Tuesday that during a review of the approval pathway for Olvi-Vec in platinum-resistant ovarian cancer, the US Food and Drug Administration recommended conducting an interim overall survival analysis alongside the primary progression-free survival analysisThe company said the agency indicated that data from the ongoing phase 3 trial could support traditional approval if it shows a \"clinically meaningful\" progression-free survival benefit without a decline in overall survival.Genelux said the FDA suggested the company request a pre-Biologics License Application meeting after topline safety and efficacy results are available. Genelux said it expects to report these results in H1 2026.Shares of the company fell 14% in recent Tuesday trading.Price: 3.29, Change: -0.60, Percent Change: -15.42","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2522496072","title":"Genelux's Olvi-Vec Shows Anti-Tumor Effect in Phase 1b/2 Lung Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522496072","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522496072?lang=en_us&edition=fundamental","pubTime":"2025-03-25 21:47","pubTimestamp":1742910471,"startTime":"0","endTime":"0","summary":"Genelux (GNLX) and Newsoara BioPharma said Tuesday that preliminary data from their co-sponsored ongoing phase 1b/2 small-cell lung cancer study indicated anti-tumor effect from Olvi-Vec immunochemoth","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GNLX","BK4139"],"gpt_icon":1},{"id":"2522797120","title":"Genelux Prices $10.5 Million Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2522797120","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522797120?lang=en_us&edition=fundamental","pubTime":"2025-03-25 21:14","pubTimestamp":1742908475,"startTime":"0","endTime":"0","summary":"Genelux  said Tuesday it has priced an underwritten offering of 3 million shares at $3.50 apiece for expected gross proceeds of $10.5 million.Net proceeds from the offering, slated to close around Wednesday, will be allocated toward working capital and general corporate purposes, the company said.Genelux shares were down more than 18% in recent Tuesday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2522977078","title":"Genelux and Newsoara Announce Positive Preliminary Phase 1B/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522977078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522977078?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:31","pubTimestamp":1742905862,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2522737080","title":"Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2522737080","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522737080?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:31","pubTimestamp":1742905860,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., March 25, 2025  -- Genelux Corporation  , a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux.Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for the offering.The net proceeds from the offering are to be used for working capital and for general corporate purposes, including the continued clinical development of Olvi-Vec. The offering is expected to close on or about March 26, 2025, subject to customary closing conditions. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genelux-corporation-announces-pricing-10-123100611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2522073059","title":"Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522073059","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522073059?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:30","pubTimestamp":1742905800,"startTime":"0","endTime":"0","summary":"- U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval -. Currently, Olvi-Vec is being evaluated in the OnPrime/GOG-3076 Phase 3 registrational trial in the United States, with the primary endpoint of progression free survival . The purpose of the FDA meeting was to discuss the FDA’s expectations with respect to the requirements necessary for the granting of traditional approval of Olvi-Vec.“We appreciate the feedback from the FDA regarding our clinical strategy for OnPrime/GOG-3076 and the plan for submission of an eventual marketing application, which could avoid the need for conducting a separate confirmatory study if the clinically meaningful PFS advantage is demonstrated,” stated Thomas Zindrick, President and CEO. “The FDA’s guidance regarding their expectations for the ongoing trial represents a significant milestone as we look forward to reporting topline safety and effic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genelux-announces-alignment-fda-key-123000034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","GNLX","BK4097","OS"],"gpt_icon":0},{"id":"2522073009","title":"Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522073009","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522073009?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:30","pubTimestamp":1742905800,"startTime":"0","endTime":"0","summary":"– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant achieving a tumor reduction of approximately 79%.– Additionally, three participants, including one individual with three prior lines of treatment, achieved stable disease at lower dose cohorts, with tumor size reductions ranging between 24% to 29.2%.– Data are supportive of Olvi-Vec being a platinum resensitizing agent beyond ovarian cancer and, consistent with earlier studies, being systemically administered in multiple solid tumor types which underscore the current clinical development strategy.Preliminary Dose Escalation Results UpdateThe primary objectives of this trial are to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of systemically administered Olvi-Vec in the target population. The data cutoff fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genelux-newsoara-announce-positive-preliminary-123000753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AEIS","BK4139","IE0031619046.USD","GNLX","IE00B66KJ199.SGD","BK4157","IE00B7SZL793.SGD","IE00B19Z4B17.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GNLX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GNLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GNLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GNLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GNLX","date":"2025-04-28","current":-3.596004,"percent":0.711896,"low":-142.534399,"twenty":-47.572676,"median":-7.19589,"eighty":-3.238277,"high":-2.158406,"avg":-26.590495,"sd":34.844686,"marketCap":107409044},"quantilePoints":[{"date":"2023-01-27","current":-23.311835,"twenty":-25.462041,"median":-24.658457,"eighty":-23.637658,"marketCap":127096126},{"date":"2023-02-03","current":-21.566357,"twenty":-24.49774,"median":-22.730009,"eighty":-22.268195,"marketCap":117579777},{"date":"2023-02-10","current":-23.19547,"twenty":-23.52905,"median":-22.574855,"eighty":-22.221416,"marketCap":126461703},{"date":"2023-02-17","current":-25.483986,"twenty":-24.428941,"median":-23.19547,"eighty":-22.272306,"marketCap":138938693},{"date":"2023-02-24","current":-42.124215,"twenty":-25.475208,"median":-23.311835,"eighty":-22.303492,"marketCap":229661220},{"date":"2023-03-03","current":-71.642196,"twenty":-40.479586,"median":-23.951844,"eighty":-22.396662,"marketCap":390593253},{"date":"2023-03-10","current":-86.575735,"twenty":-64.730101,"median":-25.462041,"eighty":-22.567098,"marketCap":472010905},{"date":"2023-03-17","current":-105.853575,"twenty":-72.642937,"median":-27.180979,"eighty":-22.66019,"marketCap":577113692},{"date":"2023-03-24","current":-116.365235,"twenty":-103.991731,"median":-38.012643,"eighty":-22.916193,"marketCap":634423260},{"date":"2023-03-31","current":-128.498675,"twenty":-109.429867,"median":-51.8795,"eighty":-23.210985,"marketCap":669092600},{"date":"2023-04-06","current":-123.681133,"twenty":-114.930063,"median":-60.587499,"eighty":-23.249773,"marketCap":644007657},{"date":"2023-04-14","current":-136.651439,"twenty":-122.489472,"median":-65.552415,"eighty":-23.373897,"marketCap":711544041},{"date":"2023-04-21","current":-132.945637,"twenty":-127.831631,"median":-79.942916,"eighty":-23.668689,"marketCap":692247931},{"date":"2023-04-28","current":-111.637277,"twenty":-127.85016,"median":-101.315331,"eighty":-23.893661,"marketCap":581295301},{"date":"2023-05-05","current":-114.416628,"twenty":-127.831631,"median":-106.803891,"eighty":-24.238878,"marketCap":595767383},{"date":"2023-05-12","current":-120.577524,"twenty":-127.85016,"median":-108.946076,"eighty":-24.999131,"marketCap":627847166},{"date":"2023-05-19","current":-52.215895,"twenty":-127.776043,"median":-106.803891,"eighty":-25.369459,"marketCap":614581090},{"date":"2023-05-26","current":-51.058006,"twenty":-125.645208,"median":-101.315331,"eighty":-25.462041,"marketCap":600952732},{"date":"2023-06-02","current":-59.704927,"twenty":-124.422293,"median":-86.575735,"eighty":-25.475208,"marketCap":702726985},{"date":"2023-06-09","current":-58.469652,"twenty":-123.792307,"median":-68.597306,"eighty":-27.520378,"marketCap":688187806},{"date":"2023-06-16","current":-74.487043,"twenty":-123.347611,"median":-68.001852,"eighty":-30.809635,"marketCap":876712493},{"date":"2023-06-23","current":-72.716483,"twenty":-122.847327,"median":-71.642196,"eighty":-33.707129,"marketCap":855873003},{"date":"2023-06-30","current":-70.077922,"twenty":-121.031485,"median":-70.328286,"eighty":-37.15154,"marketCap":824817138},{"date":"2023-07-07","current":-74.790764,"twenty":-119.048881,"median":-70.578804,"eighty":-40.479586,"marketCap":880287297},{"date":"2023-07-14","current":-75.041205,"twenty":-117.845611,"median":-72.135031,"eighty":-45.3635,"marketCap":883234986},{"date":"2023-07-21","current":-53.336544,"twenty":-116.908273,"median":-71.193522,"eighty":-47.741691,"marketCap":627771120},{"date":"2023-07-28","current":-51.570433,"twenty":-116.365235,"median":-70.453545,"eighty":-46.48399,"marketCap":606983997},{"date":"2023-08-04","current":-48.126517,"twenty":-116.05767,"median":-70.077922,"eighty":-45.46852,"marketCap":566449107},{"date":"2023-08-11","current":-59.164709,"twenty":-115.713659,"median":-66.033149,"eighty":-46.152888,"marketCap":696368627},{"date":"2023-08-18","current":-41.602632,"twenty":-115.206443,"median":-65.552415,"eighty":-44.043398,"marketCap":614512475},{"date":"2023-08-25","current":-42.347119,"twenty":-114.930063,"median":-62.598083,"eighty":-42.357754,"marketCap":625509289},{"date":"2023-09-01","current":-42.861169,"twenty":-114.622002,"median":-61.261966,"eighty":-42.357754,"marketCap":633102328},{"date":"2023-09-08","current":-43.162509,"twenty":-114.37957,"median":-59.164709,"eighty":-42.354209,"marketCap":637553420},{"date":"2023-09-15","current":-39.138735,"twenty":-114.249867,"median":-58.459358,"eighty":-41.198482,"marketCap":578118255},{"date":"2023-09-22","current":-48.923419,"twenty":-114.129419,"median":-57.852015,"eighty":-41.198482,"marketCap":722647819},{"date":"2023-09-29","current":-42.595281,"twenty":-113.290976,"median":-56.838735,"eighty":-41.198482,"marketCap":629174894},{"date":"2023-10-06","current":-43.818366,"twenty":-111.887419,"median":-55.146807,"eighty":-41.811265,"marketCap":647241090},{"date":"2023-10-13","current":-34.441378,"twenty":-110.859817,"median":-53.027474,"eighty":-40.816297,"marketCap":508733591},{"date":"2023-10-20","current":-35.469479,"twenty":-109.429867,"median":-52.256881,"eighty":-40.120748,"marketCap":523919668},{"date":"2023-10-27","current":-30.009909,"twenty":-109.166106,"median":-52.215895,"eighty":-39.776867,"marketCap":443276361},{"date":"2023-11-03","current":-29.212244,"twenty":-108.893186,"median":-51.624173,"eighty":-39.121009,"marketCap":431494060},{"date":"2023-11-10","current":-23.203172,"twenty":-107.974951,"median":-51.327593,"eighty":-37.401599,"marketCap":342734056},{"date":"2023-11-17","current":-14.007429,"twenty":-106.233701,"median":-50.410039,"eighty":-35.664463,"marketCap":350535909},{"date":"2023-11-24","current":-11.850797,"twenty":-105.807029,"median":-49.167197,"eighty":-34.147678,"marketCap":296566203},{"date":"2023-12-01","current":-12.704909,"twenty":-103.099598,"median":-48.485514,"eighty":-29.078535,"marketCap":317940344},{"date":"2023-12-08","current":-12.865055,"twenty":-96.730541,"median":-47.767313,"eighty":-25.551293,"marketCap":321947995},{"date":"2023-12-15","current":-15.81174,"twenty":-89.415047,"median":-46.735705,"eighty":-25.17429,"marketCap":395688781},{"date":"2023-12-22","current":-14.914922,"twenty":-81.570719,"median":-45.433198,"eighty":-24.679738,"marketCap":373245933},{"date":"2023-12-29","current":-17.285082,"twenty":-78.050822,"median":-45.218711,"eighty":-23.893661,"marketCap":432559174},{"date":"2024-01-05","current":-14.733424,"twenty":-77.501161,"median":-45.076904,"eighty":-23.437615,"marketCap":368703928},{"date":"2024-01-12","current":-13.580373,"twenty":-76.206894,"median":-44.79329,"eighty":-23.102378,"marketCap":339848838},{"date":"2024-01-19","current":-13.32414,"twenty":-75.817396,"median":-44.261513,"eighty":-22.44313,"marketCap":333436596},{"date":"2024-01-26","current":-11.637269,"twenty":-75.513131,"median":-44.137432,"eighty":-22.079605,"marketCap":291222668},{"date":"2024-02-02","current":-11.284948,"twenty":-75.168702,"median":-43.818366,"eighty":-15.963344,"marketCap":282405835},{"date":"2024-02-09","current":-10.003781,"twenty":-74.89094,"median":-43.357494,"eighty":-15.136992,"marketCap":250344624},{"date":"2024-02-16","current":-8.808025,"twenty":-74.608531,"median":-43.002976,"eighty":-14.878623,"marketCap":220420827},{"date":"2024-02-23","current":-7.345359,"twenty":-74.235147,"median":-42.861169,"eighty":-14.603172,"marketCap":183817610},{"date":"2024-03-01","current":-7.793768,"twenty":-73.638421,"median":-42.559829,"eighty":-14.295691,"marketCap":195039034},{"date":"2024-03-08","current":-6.843569,"twenty":-73.072652,"median":-42.347119,"eighty":-13.904936,"marketCap":171260303},{"date":"2024-03-15","current":-6.651393,"twenty":-72.681036,"median":-42.147037,"eighty":-13.535532,"marketCap":166451121},{"date":"2024-03-22","current":-6.501924,"twenty":-72.536796,"median":-40.929049,"eighty":-13.260082,"marketCap":162710646},{"date":"2024-03-28","current":-6.427189,"twenty":-72.248593,"median":-40.539079,"eighty":-12.880002,"marketCap":160840409},{"date":"2024-04-05","current":-4.418278,"twenty":-71.552461,"median":-40.131384,"eighty":-12.440135,"marketCap":125024022},{"date":"2024-04-12","current":-3.997935,"twenty":-71.070578,"median":-39.776867,"eighty":-11.850797,"marketCap":113129559},{"date":"2024-04-19","current":-3.605614,"twenty":-70.578804,"median":-39.39576,"eighty":-11.611646,"marketCap":102028060},{"date":"2024-04-26","current":-3.101202,"twenty":-70.5287,"median":-38.536055,"eighty":-11.287083,"marketCap":87754704},{"date":"2024-05-03","current":-3.250657,"twenty":-70.28711,"median":-37.242066,"eighty":-10.563224,"marketCap":91983847},{"date":"2024-05-10","current":-3.75507,"twenty":-70.11351,"median":-35.735367,"eighty":-9.228675,"marketCap":106257202},{"date":"2024-05-17","current":-3.708966,"twenty":-69.513292,"median":-35.496067,"eighty":-8.748237,"marketCap":95628265},{"date":"2024-05-24","current":-4.739234,"twenty":-67.040816,"median":-33.707129,"eighty":-8.406592,"marketCap":122191672},{"date":"2024-05-31","current":-3.43683,"twenty":-66.184999,"median":-30.009909,"eighty":-7.911208,"marketCap":88611778},{"date":"2024-06-07","current":-3.329317,"twenty":-65.881298,"median":-28.451291,"eighty":-7.345359,"marketCap":85839785},{"date":"2024-06-14","current":-3.144355,"twenty":-65.796172,"median":-25.658206,"eighty":-7.057097,"marketCap":81070908},{"date":"2024-06-21","current":-3.037757,"twenty":-65.641405,"median":-25.473014,"eighty":-6.862786,"marketCap":78322484},{"date":"2024-06-28","current":-2.931169,"twenty":-65.552415,"median":-25.462041,"eighty":-6.790187,"marketCap":75574327},{"date":"2024-07-05","current":-2.558111,"twenty":-65.304169,"median":-25.161881,"eighty":-6.636446,"marketCap":65955776},{"date":"2024-07-12","current":-3.397491,"twenty":-63.845726,"median":-24.922582,"eighty":-6.412242,"marketCap":87597515},{"date":"2024-07-15","current":-3.131021,"twenty":-63.49663,"median":-24.838384,"eighty":-6.352454,"marketCap":80727122},{"date":"2024-08-02","current":-2.611405,"twenty":-63.137211,"median":-24.754186,"eighty":-6.326831,"marketCap":67329855},{"date":"2024-08-09","current":-2.74464,"twenty":-61.691783,"median":-23.951844,"eighty":-5.040073,"marketCap":70765052},{"date":"2024-08-16","current":-2.757167,"twenty":-61.581015,"median":-23.46906,"eighty":-4.631925,"marketCap":73169689},{"date":"2024-08-23","current":-2.827067,"twenty":-60.950558,"median":-23.218715,"eighty":-4.373441,"marketCap":75024703},{"date":"2024-08-30","current":-2.54436,"twenty":-59.596883,"median":-22.730009,"eighty":-3.956329,"marketCap":67522233},{"date":"2024-09-06","current":-3.636636,"twenty":-59.164709,"median":-22.536067,"eighty":-3.760479,"marketCap":96509050},{"date":"2024-09-13","current":-3.431031,"twenty":-59.087289,"median":-22.264549,"eighty":-3.708966,"marketCap":91052708},{"date":"2024-09-20","current":-3.045522,"twenty":-58.469652,"median":-21.876664,"eighty":-3.631367,"marketCap":80822067},{"date":"2024-09-27","current":-2.711414,"twenty":-58.449064,"median":-16.660513,"eighty":-3.586932,"marketCap":71955511},{"date":"2024-10-04","current":-2.994121,"twenty":-57.913779,"median":-15.81174,"eighty":-3.514645,"marketCap":79457981},{"date":"2024-10-11","current":-3.36678,"twenty":-57.852015,"median":-15.12845,"eighty":-3.421798,"marketCap":89347601},{"date":"2024-10-18","current":-3.610936,"twenty":-57.810839,"median":-14.914922,"eighty":-3.409454,"marketCap":95827007},{"date":"2024-10-25","current":-3.238277,"twenty":-57.678368,"median":-14.786806,"eighty":-3.397922,"marketCap":85937387},{"date":"2024-10-31","current":-4.279151,"twenty":-56.334956,"median":-14.621322,"eighty":-3.397836,"marketCap":113560119},{"date":"2024-11-08","current":-3.739439,"twenty":-55.418609,"median":-14.519896,"eighty":-3.403849,"marketCap":99237221},{"date":"2024-11-15","current":-3.777989,"twenty":-55.172143,"median":-14.220956,"eighty":-3.405331,"marketCap":100260285},{"date":"2024-11-22","current":-3.032945,"twenty":-54.261172,"median":-14.007429,"eighty":-3.391652,"marketCap":83891259},{"date":"2024-11-29","current":-3.316777,"twenty":-53.617832,"median":-13.719166,"eighty":-3.36164,"marketCap":91742051},{"date":"2024-12-06","current":-3.242797,"twenty":-52.965661,"median":-13.543005,"eighty":-3.348789,"marketCap":89695760},{"date":"2024-12-13","current":-3.107167,"twenty":-52.599193,"median":-13.494962,"eighty":-3.341079,"marketCap":85944227},{"date":"2024-12-20","current":-2.700276,"twenty":-52.362016,"median":-13.094597,"eighty":-3.316777,"marketCap":74689625},{"date":"2024-12-27","current":-3.033186,"twenty":-52.240487,"median":-12.902423,"eighty":-3.276828,"marketCap":83897935},{"date":"2025-01-03","current":-2.971536,"twenty":-52.183106,"median":-12.688894,"eighty":-3.253321,"marketCap":82192693},{"date":"2025-01-10","current":-3.144157,"twenty":-52.051952,"median":-12.459352,"eighty":-3.242797,"marketCap":86967372},{"date":"2025-01-17","current":-3.057846,"twenty":-51.655055,"median":-12.288529,"eighty":-3.225426,"marketCap":84580032},{"date":"2025-01-24","current":-4.142889,"twenty":-51.605645,"median":-11.850797,"eighty":-3.225426,"marketCap":114592302},{"date":"2025-01-31","current":-4.8457,"twenty":-51.575005,"median":-11.669299,"eighty":-3.235707,"marketCap":134032068},{"date":"2025-02-07","current":-5.462202,"twenty":-51.376161,"median":-11.445094,"eighty":-3.238277,"marketCap":151084494},{"date":"2025-02-14","current":-6.732194,"twenty":-51.111923,"median":-11.290287,"eighty":-3.241687,"marketCap":186212491},{"date":"2025-02-21","current":-5.943073,"twenty":-51.02161,"median":-11.124802,"eighty":-3.242694,"marketCap":164385386},{"date":"2025-02-28","current":-5.314241,"twenty":-50.292578,"median":-10.462866,"eighty":-3.247513,"marketCap":146991912},{"date":"2025-03-07","current":-4.5991,"twenty":-49.575677,"median":-9.582064,"eighty":-3.250657,"marketCap":127211097},{"date":"2025-03-14","current":-4.414149,"twenty":-49.118441,"median":-9.053582,"eighty":-3.258649,"marketCap":122095370},{"date":"2025-03-21","current":-4.90735,"twenty":-48.731979,"median":-8.770658,"eighty":-3.263977,"marketCap":135737310},{"date":"2025-03-28","current":-4.08544,"twenty":-48.53305,"median":-8.647879,"eighty":-3.271688,"marketCap":113003265},{"date":"2025-04-04","current":-3.121531,"twenty":-48.270116,"median":-8.17278,"eighty":-3.258649,"marketCap":93237017},{"date":"2025-04-11","current":-2.921753,"twenty":-47.983088,"median":-7.911208,"eighty":-3.242694,"marketCap":87269848},{"date":"2025-04-17","current":-3.208934,"twenty":-47.791344,"median":-7.761738,"eighty":-3.230566,"marketCap":95847653},{"date":"2025-04-25","current":-3.883185,"twenty":-47.597503,"median":-7.270625,"eighty":-3.238277,"marketCap":115986849},{"date":"2025-04-28","current":-3.596004,"twenty":-47.572676,"median":-7.19589,"eighty":-3.238277,"marketCap":107409044}],"updateTime":1745932435483}}}